The Effects of Glucagon on Hepatic Metabolism in People With Type 2 Diabetes After Caloric Restriction

Launched by ADRIAN VELLA · Aug 11, 2022

Keywords

ClinConnect Summary

This clinical trial is exploring how caloric restriction, which means eating fewer calories, affects the way glucagon works in the liver of people with type 2 diabetes. Glucagon is a hormone that helps control blood sugar levels. The researchers want to see if eating less can improve the liver's ability to manage amino acids, carbohydrates, and fats in people with type 2 diabetes. This study is particularly focused on comparing the effects of caloric restriction on glucagon's actions to what happens in people with type 2 diabetes who are not on a caloric restriction plan.

To participate in this study, you should be between 18 and 75 years old, have type 2 diabetes that is managed with diet or oral medications, and have a body mass index (BMI) of 28 or higher. However, individuals with certain health issues, prior upper abdominal surgeries, or specific medical conditions may not be eligible. If you join the trial, you can expect to be part of a controlled environment where your dietary intake and health will be monitored. This research aims to provide more insights into how dietary changes can help manage diabetes effectively.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • We will recruit up to 20 weight-stable, subjects with type 2 diabetes
• • BMI ≥ 28 Kg/M2
• • Diabetes is managed by diet alone or a combination of oral agents
• Exclusion Criteria:
• • History of prior upper abdominal surgery e.g. gastric banding, pyloroplasty, vagotomy.
• • Active systemic illness or malignancy.
• • Symptomatic macrovascular or microvascular disease.
• • Contraindications to MRI (e.g. metal implants, claustrophobia).
• • Hematocrit \< 35%
• • TSH \< 0.4 or \> 5.5.
• • Consumption of \> 2 alcohol drinks per day or \> 14 per week or a positive AUDIT questionnaire.